Trials / Withdrawn
WithdrawnNCT02771158
Midodrine During Recovery From Septic Shock
A Randomized Controlled Trial of Midodrine During Recovery Phase From Septic Shock
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Northwell Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Midodrine | midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure |
| DRUG | placebo | placebo will be administered to double blind the study |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2016-05-12
- Last updated
- 2017-11-06
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02771158. Inclusion in this directory is not an endorsement.